COMMUNIQUÉS West-GlobeNewswire

iTeos Therapeutics présente les données intermédiaires de l’essai clinique A2A-005, ainsi que les données translationnelles et précliniques relatives à l’inupadénant lors du congrès d’immuno-oncologie de l’ESMO
13/12/2024
- L’essai de phase 2 A2A-005 portant sur l’inupadénant + carboplatine/pémétrexed a démontré un taux de réponse globale (TRG) de 63,9 % et une SSP médiane de 7,7 mois pour tous les patients évaluables sur l’ensemble des [...]
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
13/12/2024
BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria [...]
Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
13/12/2024
INX-315 was safe and well tolerated in monotherapy dose escalation INX-315 monotherapy demonstrated antitumor activity in heavily pretreated patients with ER+/HER2- breast cancer and CCNE1-amplified ovarian cancer [...]
Dentsply Sirona Declares Quarterly Cash Dividend
13/12/2024
CHARLOTTE, N.C., Dec. 13, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of [...]
At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy
13/12/2024
With its adoption of “zero-footprint” technology, ZEfiRO guarantees clinician and operators immediacy and usability in reading images wherever they are, with a positive impact on the management of diagnosis and [...]
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
13/12/2024
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent [...]
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13/12/2024
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13/12/2024
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
13/12/2024
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the [...]
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
13/12/2024
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
The Ensign Group, Inc. Increases Quarterly Dividend to $0.0625 Per Share
13/12/2024
SAN JUAN CAPISTRANO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
‘A Tragedy in the Making’: Approval of Canada’s Proposed $32.5 Billion Big Tobacco Settlement Risks Leaving Millions Living with Lung Disease Behind, Warns National Lung Health Alliance (NLHA)
13/12/2024
Leading patient advocacy network urges provinces to use settlement pay-outs solely to combat lung disease following historic creditors vote on December 12 TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The National Lung [...]
La formulation sous-cutanée de DARZALEX® (daratumumab) démontre une réduction de 51 pour cent du risque de progression vers un myélome multiple actif chez des patients atteints d’un myélome multiple indolent à haut risque
13/12/2024
Le premier traitement sous-cutané anti-CD38 à démontrer un potentiel de prévention des lésions au niveau des organes cibles et de prolongation de la survie sans progression et de la survie globale, d’après les résultats [...]
ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
13/12/2024
Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew Cavey and Chief [...]
Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
13/12/2024
London, UK – 13 th December 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle [...]
Candel Therapeutics Announces $80 Million Proposed Public Offering
12/12/2024
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help [...]
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
12/12/2024
No impact at this time on the listing of the Company’s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” [...]
NeuroPace to Host Investor Day on January 28th in New York City
12/12/2024
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will [...]
Results of Scheme Meeting
12/12/2024
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“ Bionomics ” or the “ Company ”) is pleased to provide the following update on the status of its proposed re [...]

Pages